Results 41 to 50 of about 2,404 (154)

Vaccinations in pregnancy: An update for a changing time

International Journal of Gynecology &Obstetrics, EarlyView.
Abstract Maternal immunization is one of the most effective public health interventions to reduce infectious morbidity and mortality in pregnant women, fetuses, and newborns. Despite robust evidence supporting vaccine safety and effectiveness in pregnancy, global uptake has declined following the COVID‐19 pandemic, contributing to resurgent outbreaks ...
Wendy Hodge, Méabh Bhuinneáin, Gelila Goba, Marisa Labovsky, Eliana Amaral, Asma Khalil, David Lissauer, Hema Divakar, Fionnuala M. McAuliffe, Deborah Money, Dharmintra Pasupathy, on behalf of the FIGO Committee on Infections During Pregnancy   +11 more
wiley   +1 more source

Effectiveness of nirsevimab among infants in their first RSV season in the United States, October 2023–March 2024: a test-negative design analysisResearch in context

The Lancet Regional Health. Americas
Summary: Background: In August 2023, the Centers for Disease Control and Prevention recommended nirsevimab, a long-acting monoclonal antibody, for all U.S. infants aged
Amanda B. Payne, Steph Battan-Wraith, Elizabeth A.K. Rowley, Melissa S. Stockwell, Sara Y. Tartof, Kristin Dascomb, Stephanie A. Irving, Brian Dixon, Sarah W. Ball, Mark W. Tenforde, Gabriela Vazquez-Benitez, Ashley B. Stephens, Jungmi Han, Karthik Natarajan, S. Bianca Salas, Cassandra Bezi, Lina S. Sy, Bruno Lewin, Tamara Sheffield, Julie Arndorfer, Daniel Bride, Josh Van Otterloo, Allison L. Naleway, Padma D. Koppolu, Shaun Grannis, William Fadel, Colin Rogerson, Tom Duszynski, Sarah E. Reese, Patrick K. Mitchell, Sean Chickery, Heidi L. Moline, Morgan Najdowski, Allison Avrich Ciesla, Emily L. Reeves, Malini DeSilva, Katherine E. Fleming-Dutra, Ruth Link-Gelles   +37 more
doaj   +1 more source

Frequency, Burden and Pathogens of Acute Respiratory Illness in Very Preterm Infants During Infancy

Acta Paediatrica, EarlyView.
ABSTRACT Aim To describe the frequency, burden, and pathogen profile of acute respiratory illnesses (ARIs) in very preterm infants during the first year after neonatal intensive care unit (NICU) discharge. Methods Very preterm infants were followed prospectively (August 2015–January 2017) with monthly assessments of symptoms, medication use, and ...
Patricia De Gouveia Belinelo, Nada Townsi, Naomi R. Hemy, Chisha T. Sikazwe, David W. Smith, Benjamin Stoecklin, J. Jane Pillow, Graham L. Hall, Ingrid A. Laing, Shannon J. Simpson   +9 more
wiley   +1 more source

A Confirmatory, Dual Center Nonhuman Primate Study on the Efficacy of Novel Oropharyngeal Spray Immunization With an Adenoviral Vector Vaccine Against RSV—Important Lessons Learned

Journal of Medical Primatology, Volume 55, Issue 6, December 2026.
ABSTRACT Background In a randomized, blinded, dual center study across two European primate research facilities, we evaluated the immunogenicity and protective efficacy of a DNA prime—oropharyngeal adenoviral boost vaccination strategy against respiratory syncytial virus (RSV).
Matthias Tenbusch, Gerrit Koopman, Petra Mooij, Berit Roshani, Pascal Irrgang, Dennis Lapuente, Ivanela Kondova, Willy M. Bogers, Edmond J. Remarque, Ramona Vestweber, Samuel Alberto Merida Ruiz, Nadine Krüger, Sebastian Meyer, Olaf Gefeller, Christiane Stahl‐Hennig, Klaus Überla   +15 more
wiley   +1 more source

Respiratory Syncytial Virus Vaccination Is Associated With Increased Odds of Preterm Birth

Acta Paediatrica, Volume 115, Issue 11, Page 2473-2477, November 2026.
ABSTRACT Aim To analyse whether respiratory syncytial virus (RSV) vaccination during pregnancy increases the odds of preterm birth. Methods A rapid review and meta‐analysis was performed. The main outcome was the risk of preterm (gestational week less than 37) birth.
Ilari Kuitunen, Marjut Haapanen
wiley   +1 more source

Optimal Respiratory Syncytial Virus intervention programmes using Nirsevimab in England and Wales [PDF]

, 2022
INTRODUCTION: Respiratory Syncytial Virus (RSV) is a major cause of acute lower respiratory tract infections (ALRI) in infants. There are no licensed vaccines and only one monoclonal antibody available to protect infants from disease.
Koltai, Mihaly, Flasche, Stefan, Jit, Mark, Atkins, Katherine E; id_orcid, Hodgson, David, Krauer, Fabienne, Atkins, Katherine E   +6 more
core   +1 more source

Post-licensure safety of nirsevimab from the Canadian National Vaccine Safety (CANVAS) network

Human Vaccines & Immunotherapeutics
Although clinical trials have shown that nirsevimab is safe, post-licensure safety data from routine clinical settings are lacking. This study describes parent-reported health events occurring within seven days of nirsevimab administration.
Marina Viñeta Paramo, Marilou Kiely, Louis Valiquette, Matthew P. Muller, Allison McGeer, Jennifer E. Isenor, Manish Sadarangani, James D. Kellner, Otto G. Vanderkooi, Kimberly Marty, Pascal M. Lavoie, Julie A. Bettinger   +11 more
doaj   +1 more source

Vaccinations During Pregnancy Protect the Mother–Infant Dyad and Are Generally Safe

Acta Paediatrica, Volume 115, Issue 11, Page 2380-2388, November 2026.
ABSTRACT Aim Vaccination in pregnancy has a critical impact on mothers, foetuses and infants. The aim of this paper was to summarise key points presented by experts attending the 12th Maria Delivoria‐Papadopoulos Perinatal Symposium in March 2025 and further expand and update them.
Ariadne Malamitsi‐Puchner, Despina D. Briana, Gian Carlo Di Renzo   +2 more
wiley   +1 more source

Efectividad de nirsevimab en la prevención de los ingresos por bronquiolitis por virus respiratorio sincitial en lactantes [PDF]

INTRODUCTION: Respiratory syncytial virus (RSV) bronchiolitis is the leading cause of hospitalization in infants. This season, a long half-life monoclonal antibody (Nirsevimab) is available to prevent this disease for all infants born from 1 April-30 ...
del Castillo, Blanca Toledo, Capozzi Bucciol, M V, González-Sánchez, M I, Ojeda Velázquez, I, Rodríguez Díaz, M, Rodríguez-Fernández, R, González-Sánchez, María Isabel, Díaz, Marta Rodríguez, Bucciol, María Victoria Capozzi, Velázquez, Inés Ojeda, Pérez-Moreno, Jimena, González-Martínez, F, Pérez-Moreno, J, Toledo Del Castillo, B, Rodríguez-Fernández, Rosa, González-Martínez, Felipe   +15 more
core   +1 more source

Safety of Re-dosing Nirsevimab Prior to RSV Season 2 in Children With Heart or Lung Disease

, 2023
International audienceAbstract In children with congenital heart disease and/or chronic lung disease entering their second respiratory syncytial virus (RSV) season, 200 mg nirsevimab had a similar safety profile to that of palivizumab and resulted in ...
Amanda Leach, Wählby Hamrén, Ulrika, Mankad, Vaishali, Cabañas, Fernando, Fernando Cabañas, Domachowske, Joseph, Nguyen, Kim A, Kubiak, Robert J, Atanasova, Victoria, Victoria Atanasova, Furuno, Kenji, Robert J Kubiak, Ulrika Wählby Hamrén, Kubiak, Robert, Therese Takas, Leach, Amanda, Banu, Irfana, Nguyen, Kim An, Manish Shroff, Chang, Yue, Kenji Furuno, Kim A Nguyen, Shroff, Manish, Takas, Therese, Joseph B Domachowske, Vaishali S Mankad, Irfana Banu, Tonya Villafana, Yue Chang, Domachowske, Joseph B, Mankad, Vaishali S, Villafana, Tonya   +31 more
core   +1 more source